In its September issue, Pharmaceutical Commerce details the previous and expected contributions of biologic products to its forecast of cold-chain market growth predicting sales of cold-chain drugs and biologics will outpace overall industry growth through 2022. It is reported that “as of 2018, global...
Wednesday, September 12, 2018 | Read More
In a recent news release the FDA described research it has conducted regarding detection of protein carbonylation, an oxidative reaction that may occur in therapeutic protein drug products during manufacture, storage, use, and transport potentially causing structural alterations and threatening stability,...
Tuesday, September 11, 2018 | Read More
Sentry BioPharma Services is pleased to announce delegates from Sentry’s Business Development team will be in New York City attending the Drug, Chemical & Associated Technologies Association (DCAT) Week March 19th -22nd. The four-day conference brings together key sourcing, procurement and business...
Monday, March 19, 2018 | Read More
Sophisticated physical and data security measures protect valuable information, pharmaceutical materials, and products while in Sentry's possession. Sentry deploys a robust security program based on industry best practices, market trends, agency intelligence and audit feedback. Sentry maintains steadfast control over product classifications and locations, with segregation capabilities for labeling, returns, quarantine, and controlled substances as well as enhanced security and anti-counterfeiting measures for high-value products. Security measures inside and outside the facility protect, monitor and control access.
Sentry's Pharmaceutical Supply Chain Security: